Business Wire

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation

11.6.2024 11:00:00 EEST | Business Wire | Press release

Share

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/

V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia.

V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video industry, such as MPEG-5 LCEVC and VC-6. It has also developed V-Nova PresenZ, a unique volumetric format that enables cinematic 6 Degrees of Freedom (6DoF) immersive experiences for the first time. Recently, V-Nova has demonstrated how its technologies drive substantial efficiencies and unique use cases in AI media indexing, multimodal Generative AI, and Intelligent Edge applications.

V-Nova’s extensive patent portfolio supports a variety of industries, including Entertainment, Social Media, Streaming, Broadcasting, Cloud Gaming, Virtual and Augmented Reality, Industrial Applications, Automotive, Security, and Defence.

“This milestone in V-Nova’s technology portfolio represents a systemic achievement tied to our company structure, strategic focus, and the highly talented individuals we have brought together,” said Guido Meardi, CEO at V-Nova.

Continuous research and development are a cornerstone of V-Nova’s technology roadmap and its resource allocation. The company has been granted 200 patents in the past 12 months alone, with 9 UK patents granted in under 200 days since the filing date. This rapid pace of innovation highlights the quality of its applications and the dedication of its team.

“V-Nova’s success is a result of its company culture, which supports diversity of opinions and encourages collaboration,” said Stergios Poularakis, Head of Advanced R&D at V-Nova. “Our team brings the right people together to interact, innovate, and create something new and exciting.”

V-Nova’s core IP development includes multi-layer and parallel data coding technology that underpins MPEG-5 LCEVC and VC-6. MPEG-5 LCEVC enables users to implement a new data layer onto an existing codec, improving visual quality, reducing energy consumption during the transcoding process, and enhancing compression efficiency. V-Nova’s innovative approach has recently unlocked new virtual reality and mixed reality use cases. The V-Nova PresenZ format enables photo-realistic immersive experiences at scale, with 6 Degrees of Freedom (6DofF) to allow viewers to ‘step inside’ cinematic content. V-Nova technologies also facilitate AI Media Indexing, Machine Vision, and Large Multimodal Models (LMMs) to interact with data like humans, efficiently processing only the necessary resolution and regions of interest while maintaining the entire signal at maximum quality in efficiently compressed form.

V-Nova continues to invest in innovative research and development. Richard Fish, Patent Attorney at V-Nova commented, “Almost 40% of employees at V-Nova are named as inventors on a patent application, making us one of the most innovative companies in the UK, if not the world.

About V-Nova

V-Nova is committed to unlocking higher quality digital experiences at scale. Its technologies, including MPEG-5 LCEVC and VC-6, are based on the innovative use of AI and parallel processing, improve data, video, imaging, and point-cloud compression, and have been granted international standard status by MPEG, ISO and SMPTE. V-Nova’s relentless investment in R&D has built a portfolio of over 1000 international patents, along with a range of software products and solutions. More about V-Nova: www.v-nova.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

V-Nova Marketing and Communications:
Joao Felix – press@v-nova.com

Bubble Agency - UK & EMEA Account Director:
Danielle Harper – danielleh@bubbleagency.com

Bubble Agency - Head of Americas:
Kim Willsher – Kimw@bubbleagency.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye